Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Methylpentynol is a tertiary acetylenic alcohol that was widely utilized in the mid-20th century as a sedative, hypnotic, and anxiolytic agent. Introduced in the early 1950s and marketed under trade names such as Oblivon and Dormison, it was primarily indicated for the short-term management of insomnia and the relief of anxiety and tension. Its pharmacological profile is characterized by central nervous system depression; research indicates it acts by inhibiting the presynaptic release of acetylcholine at both the neuromuscular junction and ganglionic synapses, and it likely modulates GABAergic neurotransmission similarly to other sedative alcohols. While it was investigated for diverse applications, including pediatric premedication and the treatment of stuttering, it proved ineffective in treating essential tremor. Methylpentynol has largely been phased out of clinical use in favor of more potent and safer alternatives, such as benzodiazepines.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methylpentynol.